ArticleEndocrine2020
Post-transplant diabetes mellitus: incidence, predicting factors and outcomes.
Article in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Association between Torque teno virus-DNA plasma loads and post-transplantation diabetes mellitus in the first year after kidney transplantation.BMC nephrology · 2026Article
- Impact of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors on Post-liver Transplant New-onset Major Adverse Cardiovascular Events, Graft Failure, Renal Outcome, and Mortality.Transplantation direct · 2026Article
- Incidence and risk factors of posttransplant diabetes mellitus in lung transplant recipients: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Risk Factors for Development of Post-Transplant Diabetes Mellitus After Kidney Transplantation and Comparison Between Older and Younger Recipients in the Early Post-Transplantation Period: A Single-Center Study.Annals of transplantation · 2025Article
- US Population Size and Outcomes of Adults on Liver Transplant Waiting Lists.JAMA network open · 2025Article
- Effect of a mobile APP-based self-care diary combined with nursing for the management of post-heart transplantation diabetes.American journal of translational research · 2024Article
- Analysis of risk factors and establishment of a risk prediction model for post-transplant diabetes mellitus after kidney transplantation.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Nutritional support in allogeneic hematopoietic stem cell transplantation Asian perspective.Blood cell therapy · 2022Review
- Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- The Influence of Microenvironment on Survival of Intraportal Transplanted Islets.Frontiers in immunology · 2022Review
- Induction of Immune Tolerance in Islet Transplantation Using Apoptotic Donor Leukocytes.Journal of clinical medicine · 2021Review
- Salivary Biomarkers and Oral Health in Liver Transplant Recipients, with an Emphasis on Diabetes.Diagnostics (Basel, Switzerland) · 2021Article
- Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.Transplant international : official journal of the European Society for Organ Transplantation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify predictors and evaluate outcomes of posttransplant diabetes mellitus (PTDM) and to investigate the effect of treatment modalities on outcomes.
methodsThe database of a tertiary medical center was searched for all adult patients without prior diabetes who underwent lung, liver, or heart transplantation between January 1, 2012 and June 30, 2018. Patients in whom PTDM (defined as HbA1C ≥ 6.5% at least 3 months post transplantation) developed during follow-up (mean 3.32 years) were identified. Risk factors for PTDM, determined by regression analysis and clinical outcomes [all-cause mortality, severe infections, graft loss, and major adverse cardiovascular events (MACE)], were compared between those who developed PTDM and those who did not; in the former, insulin-based therapy was compared with non-insulin regimen.
resultsThe cohort included 281 transplant recipients: 158 lung, 109 liver, and 14 heart. PTDM was diagnosed in 60 (21.35%) patients at a mean of 11.3 ± 12.89 months post transplantation. The only significant independent risk factor for PTDM was age (HR 1.028, 95% CI = 1.002-1.054, P = 0.0314). PTDM was associated with higher rates of severe infections (HR 2.565, 95% CI = 1.626-4.050, P < 0.0001), MACE (HR 1.856, 95% CI = 1.013-3.401, P = 0.0454) and death (HR 1.840, 95% CI = 1.024-3.304, P = 0.0413). Recipients treated with insulin-based regimens had a higher risk of severe infections (HR 2.579, 95% CI = 1.640-4.055, P < 0.0001), MACE (1.925, 95% CI = 1.074-3.451, P = 0.0278) and death (HR 1.960, 95% CI = 1.071-3.586, P = 0.0291).
conclusionsPTDM is associated with increased mortality and poor outcomes in lung, liver, and heart transplant recipients. Early identification and aggressive treatment of PTDM and its associated cardiometabolic risk factors may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.